TY - JOUR
T1 - Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma
AU - Lorenc, Rachel
AU - Shouval, Roni
AU - Flynn, Jessica R.
AU - Devlin, Sean M.
AU - Saldia, Amethyst
AU - De Abia, Alejandro Luna
AU - De Lapuerta, Magdalena Corona
AU - Tomas, Ana Alarcon
AU - Cassanello, Giulio
AU - Leslie, Lori A.
AU - Rejeski, Kai
AU - Lin, Richard J.
AU - Scordo, Michael
AU - Shah, Gunjan L.
AU - Palomba, M. Lia
AU - Salles, Gilles
AU - Park, Jae
AU - Giralt, Sergio A.
AU - Perales, Miguel Angel
AU - Ip, Andrew
AU - Dahi, Parastoo B.
N1 - Publisher Copyright:
© 2024 The American Society for Transplantation and Cellular Therapy
PY - 2024/10
Y1 - 2024/10
N2 - Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T cell therapy is becoming more relevant. The aim of this study is to determine the incidence of subsequent malignancies in adult patients with B-NHL. We retrospectively studied 355 patients from 2 different medical centers treated with four different CAR T cell products from 2016 to 2022. The overall cumulative incidence for subsequent malignancies at 36 months was 14% (95% CI: 9.2%, 19%). Subsequent malignancies were grouped into 3 primary categories: solid tumor, hematologic malignancy, and dermatologic malignancy with cumulative incidences at 36 months of 6.1% (95% CI: 3.1%-10%), 4.5% (95% CI: 2.1%-8.1%) and 4.2% (95% CI: 2.1%-7.5%) respectively. Notably, no cases of T cell malignancies were observed. In univariable analysis, increasing age was associated with higher risk for subsequent malignancy. While the overall benefits of CAR T products continue to outweigh their potential risks, more studies and longer follow ups are needed to further demonstrate the risks, patterns, and molecular pathways that lead to the development of subsequent malignancies.
AB - Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T cell therapy is becoming more relevant. The aim of this study is to determine the incidence of subsequent malignancies in adult patients with B-NHL. We retrospectively studied 355 patients from 2 different medical centers treated with four different CAR T cell products from 2016 to 2022. The overall cumulative incidence for subsequent malignancies at 36 months was 14% (95% CI: 9.2%, 19%). Subsequent malignancies were grouped into 3 primary categories: solid tumor, hematologic malignancy, and dermatologic malignancy with cumulative incidences at 36 months of 6.1% (95% CI: 3.1%-10%), 4.5% (95% CI: 2.1%-8.1%) and 4.2% (95% CI: 2.1%-7.5%) respectively. Notably, no cases of T cell malignancies were observed. In univariable analysis, increasing age was associated with higher risk for subsequent malignancy. While the overall benefits of CAR T products continue to outweigh their potential risks, more studies and longer follow ups are needed to further demonstrate the risks, patterns, and molecular pathways that lead to the development of subsequent malignancies.
KW - Chimeric antigen receptor (CAR) T-cells
KW - Diffuse large B cell lymphoma
KW - Follicular lymphoma
KW - Myelodysplastic syndrome
KW - Non-Hodgkin lymphoma
KW - Subsequent malignancy
KW - T cell malignancy
KW - late effects
UR - http://www.scopus.com/inward/record.url?scp=85201366287&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2024.06.027
DO - 10.1016/j.jtct.2024.06.027
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38972512
AN - SCOPUS:85201366287
SN - 2666-6375
VL - 30
SP - 990
EP - 1000
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 10
ER -